================================================================================


                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                       ----------------------------------

                                   FORM 10-Q

                       ----------------------------------

 (Mark One)

[X]   QUARTERYLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

                                            For the quarter ended March 31, 2010

[ ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                                 For the transition period from _____ to _______

                       Commission file number: 333-103780
                       ----------------------------------

                          ARKSON NEUTRACEUTICALS CORP.
--------------------------------------------------------------------------------
              (Exact name of small business issuer in its charter)

            Delaware                                        51-0383940
---------------------------------                       ------------------
 (State or other jurisdiction of                         (I.R.S. Employer
  incorporation or organization)                        Identification No.)

                27 Chicora Ave                                 M5R 1T7
            Toronto Ontario, Canada
------------------------------------------              -------------------
   (Address of principal executive offices)                  (Zip Code)

                   Issuer's telephone number: (416) 928-3095

      Securities Registered Under Section 12(b) of the Exchange Act: None

         Securities Registered Under Section 12(g) of the Exchange Act:
                         Common Stock, $0.001 par value
                         ------------------------------
                                (Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer as
defined in Rule 405 of the Securities Act. Yes No [X]

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes No [X]

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-Q.

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act. (Check one):


  Large accelerated filer                    Accelerated filer

  Non-accelerated  (Do not check if a smaller Smaller reporting company [X]
  reporting company) filer

Indicate by check mark whether the registrant is a shell company (as defined by
Rule 12b-2 of the Act). Yes [X] No

The Company's stock is traded on the OTC-BB. As of March 31, 2010, there were
152,889 shares of stock held by non-affiliates. As of March 31, 2010, 645,889
shares of the common stock of the registrant were outstanding.


<PAGE>

PART I - FINANCIAL INFORMATION


Item 1.  Financial Statements
-----------------------------

                          ARKSON NUTRACEUTICALS CORP.
                                 Balance Sheets


                                                     March 31,        June 30,
                                                       2010             2009
                                                   -------------   -------------
                                                    (Unaudited)      (Audited)

                  Assets

Cash                                               $          --   $         --
                                                   -------------   -------------
         Total current assets                                 --             --
                                                   -------------   -------------

         Total assets                              $          --   $         --
                                                   =============   =============

   Liabilities and Stockholders' Equity (Deficit)

Current liabilities:
  Accounts Payable and accrued expenses            $       2,000   $      2,500
  Note payable - related party                                --         11,606
  Note payable                                            12,606          1,000
  Shareholder loan                                         6,624             --
                                                   -------------   -------------
         Total current liabilities                        21,230         15,106
                                                   =============   =============

Commitments and contingencies

Stockholders' equity (deficit):
  Preferred stock, $.001 par value, 50,000,000
    shares authorized, none issued or outstanding              --            --
  Common stock, $.001 par value; 200,000,000
    shares authorized, authorized, 645,889
    shares issued and outstanding respectively               155            155
  Additional paid-in capital                             126,225        126,225
  Retained earnings                                           --             --
  Deficit accumulated during development stage          (147,610)      (141,486)
                                                   -------------   -------------

         Total stockholders' equity (deficit)            (21,230)       (15,106)
                                                   -------------   -------------

         Total liabilities and stockholders'
         equity (deficit)                          $          --   $         --
                                                   =============   =============




   The accompanying notes are an integral part of these financial statements



                                       2
<PAGE>
<TABLE>
<CAPTION>
                                          ARKSON NUTRACEUTICALS CORP.
                                           Statements of Operations
                                                  (unaudited)


                                                                                                   October 2,
                                                                                                     1998
                                                                                                  (Inception)
                                       Three-Month Period Ended       Nine-Month Period ended       Through
                                              March 31,                    March 31,               March 31,
                                         2010           2009         2010          2009              2010
                                     -------------  -------------  -------------  -------------  -------------
<S>                                  <C>            <C>            <C>            <C>            <C>
Revenue                                         --             --             --             --            --
                                     -------------  -------------  -------------  -------------  -------------

Operating expenses:

   Advertising                                  --             --             --             --         2,198
   Bank Charges and Expense                     --             --             --             --         1,102
   Dues, subscription and membership            --             --             --             --         1,005
   Miscellaneous expenses                                      --                            --           152
   Office expense                            1,056             --          1,841             --         3,257
   Professional expense                      2,283             --          4,283             --        96,431
   Rent                                         --             --             --             --        27,796
   Travel and entertainment                     --             --             --             --        15,893
                                     -------------  -------------  -------------  -------------  -------------

Total operating expenses             $       3,339  $          --  $       6,124  $          --       147,834
                                     -------------  -------------  -------------  -------------  -------------

      Operating income (Loss)               (3,339)            --         (6,124)            --      (147,834)
                                     -------------  -------------  -------------  -------------  -------------

      Other income (Expense)                    --             --             --             --           290
      Interest Income                           --             --             --             --           194
                                     -------------  -------------  -------------  -------------  -------------
      Other income                              --             --             --             --           484

      Income tax
      Current income tax                        --             --             --             --          (260)
      Income tax benefit                        --             --             --             --            --
                                     -------------  -------------  -------------  -------------  -------------

   Net income (Loss)                        (3,339)            --         (6,124)            --      (147,610)
                                     =============  =============  =============  =============  =============


Basic and diluted loss per share     $          --  $          --             --  $          --
                                     =============  =============  =============  =============

Basic and diluted weighted average
   common shares outstanding               645,889      1,967,222        645,889      1,967,222
                                     =============  =============  =============  =============

Diluted weighted average common
shares outstanding                         645,889      1,967,222        645,889      1,967,222
                                     =============  =============  =============  =============



                   The accompanying notes are an integral part of these financial statements
</TABLE>



                                                       3
<PAGE>
                          ARKSON NUTRACEUTICALS CORP.
                            Statements of Cash Flows
                                  (unaudited)


                                                                     October 2,
                                                                       1998
                                                                    (Inception)
                                           Nine-Months Ended          Through
                                               March 31,             March 31,
                                          2010           2009          2010
                                     -------------  -------------  -------------

Cash flows from operating activities:
  Net loss                           $      (6,124) $          --  $   (147,610)
  Adjustments to reconcile net loss
    to net cash used in
    operating activities:
    Increase in Accounts Payable
    Increase in Accrued Expenses              (500)            --         4,500
                                     -------------  -------------  -------------
         Net cash provided by
         (used in) operations               (6,624)            --      (143,110)

Cash flows from (used in) investing
activities:
                                     -------------  -------------  -------------
         Net cash used in
         investing activities                   --             --            --
                                     -------------  -------------  -------------

Cash flows from financing activities:
  Loan from officer/shareholder              6,624             --       (35,760)
  Loan from related party                       --             --        54,990
  Issuance of common stock                      --             --       123,880
                                     -------------  -------------  -------------
         Net cash provided by
         financing activities                6,624             --       143,110
                                     -------------  -------------  -------------

         Net change in cash                     --             --            --

Cash, beginning of period                       --             --            --
                                     -------------  -------------  -------------

Cash, end of period                  $          --  $          --  $         --
                                     =============  =============  =============

Supplemental disclosure of cash
 flow information:
  Interest paid                      $          --             --  $          --
                                     =============  =============  =============
  Income taxes paid                  $          --  $          --  $        260
                                     =============  =============  =============





   The accompanying notes are an integral part of these financial statements




                                       4
<PAGE>

                          ARKSON NUTRACEUTICALS CORP.
                         (A Development Stage Company)
                         Notes to Financial Statements
                            March 31, 2010 and 2009

NOTE 1- UNAUDITED INFORMATION

The balance sheet of Arkson Nutraceuticals Corp. (the "Company"), as of March
31, 2010, and the statements of operations and cash flows for the three month
and nine month periods ended March 31, 2010 and 2009, have not been audited.
However, in the opinion of management, such information includes all adjustments
(consisting only of normal recurring adjustments) which are necessary to
properly reflect the financial position of the Company as of March 31, 2010, and
the results of operations for the three months and nine months ended March 31,
2010 and 2009.

Certain information and notes normally included in financial statements prepared
in accordance with accounting principles generally accepted in the United States
of America have been condensed or omitted, although management believes that the
disclosures are adequate to make the information presented not misleading.
Interim period results are not necessarily indicative of the results to be
achieved for an entire year. These financial statements should be read in
conjunction with the financial statements and notes to financial statements
included in the Company's consolidated financial statements as filed on Form
10-K for the year ended June 30, 2009.

NOTE 2 - STOCKHOLDERS' EQUITY

COMMON STOCK

Effective August 7, 2008 the Company amended its Articles of Incorporation
increasing its authorized share capital. As a result, the Company now has
authorized two hundred million (200,000,000) shares of common stock, having one
tenth of a cent ($0.001) par value per share, and fifty million (50,000,000)
shares of preferred stock, also having one hundredth of a cent ($0.0001) par
value per share.

On October 2, 1998 the Company issued a total of 9,250,000 shares to its three
founders for services rendered in connection with the organization of the
Company. Also in 1998 the Company issued 600,000 shares of common stock for
cash, net of offering costs, in the amount of $6,000. Also in 1998 the Company
issued 1,000,000 shares of common stock for cash, net of offering costs, in the
amount of $50,000. In 1999 the Company issued 16,000 shares of common stock for
cash, net of offering costs, in the amount of $16,000.

In 2000 the Company issued 50,000 shares of common stock for cash, net of
offering costs, in the amount of $50,000, and also issued 1,780 shares for
services valued at $1,780.

In the first quarter of 2007 the Company voted to issue 39,000,000 shares of
common stock to its president in exchange for services, however this issuance
was cancelled before it took effect.



                                       5
<PAGE>

Effective August 7, 2008 the Company reverse split its issued and outstanding
common stock on the basis of one new share for each twenty old shares.

The Company issued 100,000 in May 2009.

As of March 31, 2010 there were 645,889 shares of common stock issued and
outstanding.

PREFERRED STOCK

The Company currently has 50,000,000 preferred shares authorized. As of March
31, 2010 there were no shares of preferred shares issued.

NOTE 3 - EARNINGS PER SHARE

Basic earnings per share are calculated on the weighted average number of common
shares outstanding during each period. Diluted earnings per share is computed by
dividing net income by the weighted average number of common shares and common
stock equivalents outstanding for the period. Common stock equivalents are
excluded from the computation if such inclusion would have an anti-dilutive
effect.

NOTE 4 - LOANS PAYABLE

Shareholders of the company have loaned the company $6,624. The loans are non
interest bearing and has no term of repayment.

NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company's financial position and
operating results raise substantial doubt about the Company's ability to
continue. The Company has had no operating revenue since inception and is
currently not operating.

The ability of the Company to continue as a going concern is dependent upon
developing sales and obtaining additional capital and financing. The financial
statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.

NOTE 6 - RELATED PARTY TRANSACTIONS

Related parties have loaned the Company $6,624. The loans are non-interest
bearing and have no terms of repayment.

NOTE 7 - SUBSEQUENT EVENT

Management has evaluated subsequent events up to and including May 5, 2010 which
is the date the statements were available for issuance and determined there is
no reportable event to disclose.


                                       6
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

FORWARD-LOOKING STATEMENTS

The discussion contained herein contains "forward-looking statements" that
involve risk and uncertainties. These statements may be identified by the use of
terminology such as "believes," "expects," "may," "should" or anticipates" or
expressing this terminology negatively or similar expressions or by discussions
of strategy. The cautionary statements made in this Form 10Q should be read as
being applicable to all related forward-looking statements wherever they appear
in this Form 10Q. Our actual results could differ materially from those
discussed in this report.

COMPANY HISTORY AND PLAN OF OPERATION

Arkson Nutraceuticals, Corp. (the "Company") was incorporated on October 2, 1998
under the laws of the State of Delaware. The Company intended to engage in the
manufacture and sale of a broad range of proprietary natural health food
supplement products. The Company began to negotiate licenses with developers of
natural health food supplements approximately one month after incorporation. The
Company also entered negotiations with various wholesale buyers of such products
and with finance organizations. No licenses or contracts were realized after
approximately three years of efforts by the Company.

As a result of the Company's failure to generate sales it operated at a loss. By
June 30, 2001 all funds raised by the sale of shares had been expended, and the
Company thereafter became dormant. From July 1, 2001 until the present, it was
inactive and could be deemed to be a so-called "shell" company, whose only
purpose at this time is to determine and implement a new business purpose. As a
"shell" company, our sole purpose at this time is to locate and consummate a
merger or acquisition with a private entity. We have not yet identified any
company or companies which we hope to merge with or acquire.

LIQUIDITY AND CAPITAL RESOURCES

The Company has no current operating history and does not have any revenues or
earnings from operations. As of March 31, 2010, the Company had no assets and
liabilities of $21,230 and it had an accumulated deficit of $147,610. Moreover,
the Company has had no revenues from inception through March 31, 2010. We will,
in all likelihood, sustain operating expenses without corresponding revenues, at
least until the closing of a merger with or acquisition of an operating
business. We expect these continued operating losses to be small since the
Company has no operations or employees. We are dependent upon our officers to
meet any costs that may occur.

RESULTS OF OPERATIONS

The Company has no revenues to date. During the nine month period ended March
31, 2010 the company incurred costs of $6,124. These costs were for audits and
transfer agent services. Our net loss since inception through March 31, 2010 was
$147,610.

GOING CONCERN

The accompanying financial statements are presented on a going concern basis.
The company's financial condition raises substantial doubt about the Company's
ability to continue as a going concern. The Company does not have significant
cash or other material assets and it is relying on advances from stockholders,
officers and directors to meet its limited operating expenses.


                                       7
<PAGE>

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to investors.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our management team, under the supervision and with the participation of our
principal executive officer and our principal financial officer, evaluated the
effectiveness of the design and operation of our disclosure controls and
procedures as such term is defined under Rule 13a-15(e) promulgated under the
Exchange Act, as of the last day of the fiscal period covered by this report.
The term disclosure controls and procedures means our controls and other
procedures that are designed to ensure that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the
SEC's rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure at a reasonable level
that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is accumulated and communicated to management,
including our principal executive and principal financial officer, or persons
performing similar functions, as appropriate to allow timely decisions regarding
required disclosure. Based on this evaluation, our principal executive officer
and our principal financial officer concluded that, as of March 31, 2010, our
disclosure controls and procedures were effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting
during the fiscal quarter ended March 31, 2010 that materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.

                           PART II - OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

We are currently not a party to any pending legal proceedings and no such
actions by, or to the best of our knowledge, against us have been threatened.



                                       8
<PAGE>

ITEM 1A - RISK FACTORS

IN ADDITION TO THE OTHER INFORMATION IN THIS REPORT, THE FOLLOWING FACTORS
SHOULD BE CONSIDERED CAREFULLY IN EVALUATING OUR BUSINESS AND PROSPECTS,

CONDITIONS EXIST WHICH CAUSE SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO CONTINUE AS
A GOING CONCERN.

Pending negotiation and consummation of a combination, the Company anticipates
that it will have, aside from carrying on its search for a combination partner,
no business activities, and, thus, will have no source of revenue. Should the
Company incur any significant liabilities prior to a combination with a private
company, it may not be able to satisfy such liabilities as are incurred.

If the Company's management pursues one or more combination opportunities beyond
the preliminary negotiations stage and those negotiations are subsequently
terminated, it is foreseeable that such efforts will exhaust the Company's
ability to continue to seek such combination opportunities before any successful
combination can be consummated. In that event, the Company is common stock will
become worthless and holders of the Company's common stock will receive a
nominal distribution, if any, upon the Company's liquidation and dissolution.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

     None

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

     None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     None

ITEM 5 - OTHER INFORMATION

None

ITEM 6 - EXHIBITS

No.      Description
---      -----------

31.1  Certification of Chief Executive Officer required by Rule 13a-14(a) or
      Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002

31.2  Certification of Chief Financial Officer required by Rule 13a-14(a) or
      Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002

32.1  Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as
      adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2  Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as
      adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



                                       9
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Date: May 5, 2010                ARKSON NUTRACEUTICALS, INC.


                                 By: /s/ David Roff
                                       --------------------------------
                                       David Roff
                                       President and Director












                                       10


--------------------------------------------------------------------------------